ArticleCPT: pharmacometrics & systems pharmacology2025
Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling.
Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy.CPT: pharmacometrics & systems pharmacology · 2026Trial
- Clinical Evaluation of Drug-Drug Interactions With Aficamten.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aficamten is a next-in-class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PK) model was developed using data from nine clinical studies to characterize aficamten PK and identify covariates that may alter aficamten exposure. Aficamten PK was best described by a 2-compartment model with linear elimination and first-order absorption following a time lag (Tlag). Population parameter estimates for a typical male participant with obstructive HCM (oHCM) and weighing 80 kg were: apparent clearance (CL/F), 2.62 L/h; apparent volume of the central compartment (Vc/F), 18.1 L; apparent intercompartmental clearance (Q/F), 57.6 L/h; and apparent volume of the peripheral compartment (Vp/F), 295 L. Estimated interindividual variability on CL/F and overall residual error (includes within-subject variability) was low; the coefficient of variation was 28.7% and 20.3%, respectively. Body weight on volume and clearance, population and sex on CL/F and Vp/F were identified as statistically significant covariates. A male patient with a baseline body weight of 56 kg (5th percentile of the population) exhibited a 23% higher AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.